{"id":397,"date":"2020-07-25T09:52:53","date_gmt":"2020-07-25T09:52:53","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=397"},"modified":"2020-07-25T09:52:53","modified_gmt":"2020-07-25T09:52:53","slug":"24-july-2020-tocilizumab-associated-with-low-mortality-and-no-major-safety-concerns-in-severe-covid-19-pneumonia","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/24-july-2020-tocilizumab-associated-with-low-mortality-and-no-major-safety-concerns-in-severe-covid-19-pneumonia\/","title":{"rendered":"(24 July 2020) Tocilizumab- associated with low mortality, and no major safety concerns in severe COVID-19 pneumonia"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p id=\"screen-reader-main-title\" class=\"Head u-font-serif u-h2 u-margin-s-ver\"><span class=\"title-text\">Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study<\/span><\/p>\n<p>https:\/\/doi.org\/10.1016\/j.jaut.2020.102523<\/p>\n<div id=\"abssec0020\">\n<p id=\"abspara0020\" class=\"\">The objective of this work was to describe the clinical characteristics and predictors of major outcomes in patients treated with tocilizumab (TCZ) for severe COVID-19 pneumonia. From a cohort of 236 patients, 77 patients treated with TCZ were included (median age 62 years (IQR 53.0\u201372.0), 64.9% were males), 42.9% had Charlson index \u22653; hypertension (41.6%), obesity (34.7%), and diabetes (20.8%). Median follow-up was 83.0 days (78.0\u201386.5), no patient was readmitted. ICU admission was required for 42 (54.5%), invasive mechanical ventilation in 38 (49.4%) and 10 patients died (12.9% global, 23.8% at ICU admitted). After multivariate adjustment, TCZ response by BCRSS (OR 0.03 (0.01\u20130.68), p = 0.028), and Charlson index (OR 3.54 (1.20\u201310.44), p = 0.022) has been identified as independent factors associated with mortality. Median of hospital stay was 16.0 days (11.0\u201323.0); BCRSS, physician subjective and D-dimer response were associated with shorter hospitalization stay. In a Mediterranean cohort, use of tocilizumab for severe COVID-19 show 12.9% of mortality. Early TCZ-response by BCRSS and low comorbidity were associated with increased survival. Early TCZ-response was related to shorter median hospital stay.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study https:\/\/doi.org\/10.1016\/j.jaut.2020.102523 The objective of this work was to describe the clinical characteristics and predictors of major outcomes in patients treated with tocilizumab (TCZ) for&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/24-july-2020-tocilizumab-associated-with-low-mortality-and-no-major-safety-concerns-in-severe-covid-19-pneumonia\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(24 July 2020) Tocilizumab- associated with low mortality, and no major safety concerns in severe COVID-19 pneumonia&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,18],"tags":[27],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/397"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=397"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/397\/revisions"}],"predecessor-version":[{"id":398,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/397\/revisions\/398"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=397"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=397"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=397"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}